GLC Medical (GLCM) Inc.
We are a Canadian graphene technology company producing platform technologies which offer new and innovative first-to-market products and solutions.
Who are we?
Following the spread of this global pandemic, GLC Medical (GLCM) Inc. was founded to carry out the research, product development and commercialization of our Covid-19 Rapid Test that uses GLC’s graphene platform technology. Our graphene technology can ultimately be tailored to detect other types of viruses and pathogen, offering a technology that can be used for developing various sensory devices for medical purposes. GLC is investing heavily on further research and development for pioneering graphene applications in Health Innovation.
Our latest project
Covid-19 Rapid Test
The race to develop a diagnostic tool for rapid testing is critical. Time is crucial in containing the spread. GLC is in development of their patent-pending Tailorable Graphene Virus Biosensor, which is an easy-to-use and simple virus detection kit. Our graphene technology can be tailored for any virus or other respiratory infection.
Having a rapid diagnostic response test kit, using saliva, enables our economy to reopen by utilizing a non-intrusive testing tool on a massive scale. This at-the-door technology allows for businesses to reopen reducing the stringent physical distancing requirements. Businesses can now ensure with a confidence their clientele are comfortably diagnosed and society can return to public venues and events.
In The News
Check out our latest news posting and publications.
Donna Mandau, President and CEO of Graphene Leaders Canada, speaks with Ryan Jespersen about creating the “world’s first” Covid-19 Rapid Detection Test.
GLCM is pleased to report it has completed development of the graphene-enhanced sensor used in the rapid test kit.
Looking for more?
We're here to answer any questions you may have about our graphene products and application solutions